The objective of our study was to evaluate the medico-surgical management of Buruli ulcer (BU) in the BU Screening and Treatment Center (CDTUB) of Allada in Benin. This retrospective and descriptive study retrospectively reviewed records of patients seen from 2010 to 2014 at the CDTUB of Allada. It included patients diagnosed with BU according to WHO epidemiological and clinical criteria as well as laboratory results and who were treated according to WHO medical and surgical recommendations. In all, 274 patients were diagnosed and treated, 57.7% of them children younger than 15 years. Ulcerative lesions (189, 69%) and WHO category II lesions (144, 52.5%) predominated. All patients received dual antibiotic therapy and 43.4% (119) underwent surgery as well. Category III lesions and multifocal lesions required more surgery, whereas most category I lesions healed under medical treatment. The overall rate of healing was 92%: 53.3% for patients who received only antibiotic therapy and 38.7% for those who also had surgery. The median healing time was 13 weeks and ranged from 4 to 56 weeks. In the CDTUB of Allada, between 2010 and 2014, most patients were treated with antibiotic therapy alone, but a significant number still received surgery.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1684/mst.2019.0929 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Volatile organic compound detection of Buruli ulcer disease: Headspace analysis of Mycobacterium ulcerans and used gauzes of Buruli-compatible ulcers.
PLoS Negl Trop Dis
September 2024
Department of Respiratory Medicine, Academic Medical Centre, Amsterdam, The Netherlands.
Article Synopsis
- - Diagnosing Buruli ulcer (BU) is challenging due to limited access to a reliable detection method, but researchers are exploring the use of volatile organic compounds (VOCs) emitted by the bacteria Mycobacterium ulcerans for diagnosis.
- - The study involved two phases: a discovery phase where specific VOCs produced by M. ulcerans were identified, and a validation phase that tested these VOCs on clinical samples from ulcer patients in the Democratic Republic of Congo.
- - Analysis of the headspace samples revealed 24 distinct VOC fragments associated with M. ulcerans, with methylcyclohexane emerging as the most effective compound, although further research is needed to confirm their potential as diagnostic biomarkers.
Buruli ulcer: Evaluation of its medical and surgical management at the Allada (Benin) Screening and Treatment Center, 2010-2014.
Med Sante Trop
November 2019
Faculté des sciences de la santé, université d'Abomey-Calavi, Bénin.
The objective of our study was to evaluate the medico-surgical management of Buruli ulcer (BU) in the BU Screening and Treatment Center (CDTUB) of Allada in Benin. This retrospective and descriptive study retrospectively reviewed records of patients seen from 2010 to 2014 at the CDTUB of Allada. It included patients diagnosed with BU according to WHO epidemiological and clinical criteria as well as laboratory results and who were treated according to WHO medical and surgical recommendations.
View Article and Find Full Text PDFBacterial diversity in Buruli ulcer skin lesions: Challenges in the clinical microbiome analysis of a skin disease.
PLoS One
September 2017
Mycobacteriology unit, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
Background: Buruli ulcer (BU) is an infectious disease caused by Mycobacterium ulcerans and considered the third most prevalent mycobacterial disease in humans. Secondary bacterial infections in open BU lesions are the main cause of pain, delayed healing and systemic illness, resulting in prolonged hospital stay. Thus, understanding the diversity of bacteria, termed the microbiome, in these open lesions is important for proper treatment.
View Article and Find Full Text PDFHistopathological changes and clinical responses of Buruli ulcer plaque lesions during chemotherapy: a role for surgical removal of necrotic tissue?
PLoS Negl Trop Dis
September 2011
Swiss Tropical and Public Health Institute, Basel, Switzerland.
Background: Buruli ulcer (BU) caused by Mycobacterium ulcerans is a necrotizing skin disease usually starting with a subcutaneous nodule or plaque, which may ulcerate and progress, if untreated, over months and years. During the currently recommended antibiotic treatment with rifampicin/streptomycin plaque lesions tend to ulcerate, often associated with retarded wound healing and prolonged hospital stays.
Methodology/principal Findings: Included in this study were twelve laboratory reconfirmed, HIV negative BU patients presenting with plaque lesions at the CDTUB in Allada, Benin.
Background: Mycobacterium ulcerans disease (Buruli ulcer) is the most widespread mycobacterial disease in the world after leprosy and tuberculosis. How M. ulcerans is introduced into the skin of humans remains unclear, but it appears that individuals living in the same environment may have different susceptibilities.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!